Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.

@article{Takeuchi2014ClinicalSO,
  title={Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.},
  author={Shinji Takeuchi and Seiji Yano},
  journal={Respiratory investigation},
  year={2014},
  volume={52 6},
  pages={348-56}
}
Gefitinib and erlotinib, which are epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs), are highly effective against lung tumors with EGFR activating mutations. However, in 20-30% of cases, there is intrinsic resistance, and even if the treatment is effective, resistance is acquired in one to several years. Possible mechanisms of acquired resistance to EGFR-TKI, thus far, include a gatekeeper mutation of EGFR, activation of an alternate pathway, activation of EGFR… CONTINUE READING